Clinical trialCLINICALTRIALS5 days ago
Researchers are looking for adults and children with certain immune system disorders to join a study. The immune system normally helps your body fight infections, but in some people it doesn't work properly, causing frequent infections and other health problems. This study wants to understand why some immune systems fail and how to help people with these conditions. Relatives of affected people may also be able to join.
WHY IT MATTERSThis trial is actively recruiting 500 participants with four specific genetic immune disorders (PI3KCD, CTLA4, STAT3GOF, and MAGT1 deficiency) — if you or a family member has one of these diagnoses, you may be eligible to enroll now and contribute to understanding these rare conditions.
Clinical trialUNITERAREApr 15
Researchers are testing a new cancer treatment that combines two approaches: a chemotherapy drug called temozolomide and a vaccine called SurVaxM that trains the immune system to fight cancer cells. This trial is for patients with neuroendocrine carcinomas (rare cancers in hormone-producing cells) that are spreading and getting worse despite other treatments. The study is now accepting patients and will run through 2026.
WHY IT MATTERSThis is one of the first trials testing an immunotherapy vaccine specifically for metastatic neuroendocrine carcinomas, offering a potential new option for patients whose cancer has progressed on standard treatments.
Clinical trialUNITERAREApr 5
Researchers are testing a new drug called CYT107 to help people with HIV who have Kaposi Sarcoma (a type of cancer) and whose immune systems aren't responding well to treatment. CYT107 is designed to boost the immune system to help fight the cancer. This is a Phase 2 trial, meaning it's testing whether the drug works and is safe in a larger group of people. The trial is now accepting patients and will start in April 2026.
WHY IT MATTERSThis trial offers a potential new treatment option for people with HIV-related Kaposi Sarcoma who haven't responded to standard immune-boosting treatments, addressing a significant gap in care for this vulnerable population.
Clinical trialUNITERAREApr 5
Researchers are looking for people with Down syndrome (Trisomy 21) to join a study about how their immune system works differently and ages over time. Some participants will have had their thymus gland removed, while others won't have, so scientists can compare how this affects immune health. The study will help doctors understand why people with Down syndrome often get more infections and have other immune-related health problems.
WHY IT MATTERSThis trial is now recruiting people with Down syndrome to help researchers understand immune system problems that affect this population — findings could lead to better treatments for infections and other immune conditions common in Trisomy 21.
Clinical trialUNITERAREApr 5
Researchers are testing a drug called baricitinib to see if it is safe and works well for patients with Job syndrome who also have lupus-like disease and/or atopic dermatitis (severe itchy skin). Job syndrome is a rare immune system disorder that makes it hard for the body to fight infections and causes skin problems. This is an early-stage study that will check for side effects and how well the drug works.
WHY IT MATTERSThis Phase 1 trial is now actively recruiting patients with Job syndrome complicated by lupus-like disease and/or atopic dermatitis — a rare combination that has limited treatment options and is being studied by the National Institute of Allergy and Infectious Diseases.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing whether two cancer-fighting drugs called atezolizumab and bevacizumab work better together for treating rare cancers. These drugs help the body's immune system recognize and attack cancer cells. The study includes 133 patients with various uncommon solid tumors and is currently enrolling participants.
WHY IT MATTERSThis trial offers patients with rare cancers like Merkel cell carcinoma, nasopharyngeal cancer, and mesothelioma access to a combination immunotherapy treatment that may not be available outside of clinical research.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing two cancer-fighting drugs called nivolumab and ipilimumab together to treat patients with rare types of cancer. These drugs help the body's immune system recognize and fight cancer cells. The trial is currently active but not accepting new patients at this time.
WHY IT MATTERSThis trial tests a combination immunotherapy approach across 50+ rare tumor types, offering potential treatment options for patients with uncommon cancers that have limited standard therapies available.
Clinical trialCLINICALTRIALSMar 26
Researchers are testing a combination of two cancer-fighting treatments called talimogene laherparepvec and nivolumab in patients with rare lymphomas (blood cancers) and skin cancers that didn't respond to previous treatments. Talimogene laherparepvec is a modified virus that helps the immune system fight cancer cells, while nivolumab is an immunotherapy drug that removes the brakes on the immune system. This study involves 68 patients and is currently enrolling participants.
WHY IT MATTERSThis trial offers a potential new treatment option for patients with refractory (treatment-resistant) rare lymphomas like mycosis fungoides and Merkel cell carcinoma, which have very limited options after standard therapies fail.